ASH Abstracts Reveal How AI-Driven Biosimulation Technology Predicts Drug Response in Individual Cancer Patients with High Accuracy
Cellworks Group, Inc., a leader in Precision Medicine and a global pioneer of Therapy Response Index (TRI) technology, announced that results from using its genomics-informed Computational Biology Modeling technology (CBM) to predict drug response within specific cancer tumors will be featured as 10 poster presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition held December 1-4, 2018 in San Diego, California.
“Over the past year, we have completed many studies using our AI-driven biosimulation technology to predict drug responses for tumors based the genomic data of each cancer patient,” said Yatin Mundkur, CEO of Cellworks. “The consistent high accuracy of these studies demonstrates tremendous promise for using AI-driven biosimulation to match the best therapy to individual patients the first time. This approach avoids the side-effects, costs and risks associated with nonresponsive treatments, and ultimately saves lives. We look forward to sharing the results of these studies with oncologists and cancer researchers at this year’s ASH meeting.”
Cellworks is transforming personalized cancer therapy through AI-driven biosimulation software models that represent bio molecular and physiological pathways using the genomic data of each patient. Cellworks personalized medicine predictions help transform lives through the early adoption of successful therapies, while saving time and cost across the healthcare ecosystem. Cellworks also benefits the biopharma industry through virtual clinical trials, improved target identification, lead validation and the ability to repurpose and rescue drugs.